Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists.
Cristina RebordosaDóra Körmendiné FarkasJukka MontonenKristina LaugesenFlorian VossJaume AguadoUlrich BothnerKenneth J RothmanKristina ZintDaniel MinesVera EhrensteinPublished in: Pharmacoepidemiology and drug safety (2022)
Olodaterol users had a similar risk for cardiac arrhythmias or myocardial ischaemia as other LABA users. The observed excess all-cause mortality associated with olodaterol use could be due to uncontrolled channelling bias.